Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 118Neoplasms 110Lung Neoplasms 65Colorectal Neoplasms 52Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 46Pancreatic Neoplasms 34Melanoma 33Ovarian Neoplasms 29Neoplastic Cells, Circulating 29Head and Neck Neoplasms 27Uterine Cervical Neoplasms 23Multiple Myeloma 20Glioma 20Colonic Neoplasms 20Carcinoma, Hepatocellular 20Sarcoma 19Leukemia, Myeloid, Acute 18Neoplasm Metastasis 17Lymphoma 15Glioblastoma 15Esophageal Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Hematologic Neoplasms 14Endometrial Neoplasms 14Leukemia 13Myelodysplastic Syndromes 11Kidney Neoplasms 11Gastrointestinal Neoplasms 11Carcinoma, Renal Cell 11

Interventions

tofacitinib 5Aprepitant 3masitinib 2desloratadine 1apremilast 1Lidocaine 1Etanercept 1Capsules 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pruritus × Blood Specimen Collection × Clear all
NCT01801670 2015-01-27

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Boston University

Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡